tbuckley/cabot-search huggingface dataset:
COVID-19 Vaccination for Caregivers in the Pediatric Medical Home
Authors: Andrea Milne Wenderlich, Cynthia Rand, Jill Halterman
Journal: JAMA Pediatrics (2021)

A Call to Action to Improve Community Vaccination RatesAt a time when safe and effective vaccines are readily available and the highly transmissible Delta variant of COVID-19 is widely circulating, COVID-19 cases are once again rising across the US.In addition to the morbidity and mortality associated with increasing rates of infection, as we approach the back-to-school season, there is significant concern about children not being able to participate in daily in-person learning if infection rates continue to rise.This is a particularly urgent issue as children have already missed out on so much in-person learning during the pandemic, with a disproportionate impact on children from racial and ethnic minority groups living in poor communities. 1hildren have experienced significant trauma from the fallout of the COVID-19 pandemic, and school and childcare shutdowns have contributed to a marked increase in behavioral health concerns along with learning loss.Minimizing the burden of COVID-19 through increased vaccination is of urgent importance to help prevent morbidity and mortality and to keep children in school.Pediatric clinicians are uniquely poised to improve community vaccination rates by vaccinating caregivers along with their own patients in the pediatric medical home.Pediatricians talk about vaccines with patients and families daily and have substantial experience discussing vaccine hesitancy and concerns.Parents rely on their pediatric clinician for vaccine information most often, and a physician's recommendation is associated with higher rates of uptake for specific vaccines. 2,3In addition, pediatricians have frequent touch points with families over time, as children are typically seen for care more frequently than their caregivers are for their own health care.Thus, the pediatric medical home represents a unique opportunity to provide a convenient and trusted space for vaccination.Pediatricians can address the major factors identified by the World Health Organization related to vaccine hesitancy: convenience, confidence, and complacency. 4Families generally have confidence in their medical home, and primary care clinicians can help those who are worried by building confidence in the safety and efficacy of the vaccine while also decreasing complacency by clearly discussing the risk of COVID-19 infection.At this point in the pandemic in the US, COVID-19 vaccines are available at numerous community locations.However, vaccine availability is insufficient for those with transportation barriers and competing job and family demands in an era of increasing vaccine hesitancy.Many individuals, particularly individuals from racial and ethnic minority groups, report vaccine hesitancy related to long-standing mistrust of histori-
Stromally expressed c-Jun regulates proliferation of prostate epithelial cells
Authors: Wenhua Li, Phillip Febbo, Aria Olumi
Journal: Cancer Research (2007)

2806  Introduction:  Stromal-epithelial interactions play an important role in development, growth and tumorigenesis of prostate. We have found that the transcription factor, c-Jun is exclusively expressed in the prostatic stroma. Here we demonstrate that stromally expressed c-Jun promotes stromal expression of IGF-1, which in turn activates downstream prostate epithelial signalling, promoting proliferation of prostate epithelial cells.  Methods:  Microarray analysis and immunohistochemistry studies were used to determine expression of RNA and proteins. c-Jun -/-, c-Jun +/+ and BPH-1 cells were used in co-culture and mono-culture experiments to assess proliferation and cell death of prostate epithelial BPH-1 cells. ELISA, Western Blot, RT-PCR assays were used to examine the expression of different genes/proteins in co-culture and mono-culture systems.  Results:  In human benign hyperplastic tissues, we found that the expression of c-Jun was restricted to the prostatic stroma by micro-array and immunohistochemical analysis. Genetically modified mouse embryonic fibroblasts, c-Jun -/- and c-Jun +/+, were used in co-cultures to examine the effect of stromally expressed c-Jun on prostatic epithelial cells, BPH-1. We found that expression of c-Jun promoted proliferation of prostate epithelial cells. Expression of IGF-1 was limited to stromal cells with wild-type c-Jun. Stromally expressed IGF-1 promoted activation of IGF-1-receptor of epithelial cells. Either exogenous IGF-1 in mono-culture experiments or stromal expression of c-Jun in co-culture experiments led to activation of phospho-ERK, phospho-Akt and Cyclin D and repression of p27. Proliferation of BPH-1 cells and increased Cyclin D levels occurred in an Akt-dependent manner.  Conclusion:  These data suggest that stromally expressed c-Jun promote prostatic epithelial proliferation through IGF-1 induced paracrine signals. Identification of the signal transduction pathways between prostate stromal and epithelial cells are critical in order to develop novel targeted therapies for treatment of BPH.
363P Clinical significance of telomerase reverse transcriptase (TERT) promoter mutations, telomere length and MGMT promoter methylation status in newly diagnosed and recurrent IDHwildtype glioblastoma (GBM) patients (PTS): A large mono-institutional study
Authors: G. Lombardi, S. Giunco, F. Cavallin, C. Angelini, M. Caccese, G. Cerretti, P. De Bonis, A. De Rossi, V. Zagonel
Journal: Annals of Oncology (2021)
Abstract 50: Risk factors for Primary Ventricular Fibrillation during Acute Myocardial Infarction: A Systematic Review and Meta-analysis.
Authors: Peter Gheeraert, Marc De Buyzere, Yves Taeymans, Thierry Gillebert, Jose Henriques, Guy De Backer, Dirk De Bacquer
Journal: Circulation (2006)

Aims To evaluate potential risk factors for primary ventricular fibrillation (PVF) during acute myocardial infarction (AMI) by a systematic review and meta-analyses. Methods and results We searched...
Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial
Authors: Louise F Hill, Michelle N Clements, Mark A Turner, Daniele Donà, Irja Lutsar, Evelyne Jacqz-Aigrain, Paul T Heath, Emmanuel Roilides, Louise Rawcliffe, Clara Alonso-Diaz, Eugenio Baraldi, Andrea Dotta, Mari-Liis Ilmoja, Ajit Mahaveer, Tuuli Metsvaht, George Mitsiakos, Vassiliki Papaevangelou, Kosmas Sarafidis, A Sarah Walker, Michael Sharland, Louise F Hill, Michelle Clements, Mark A Turner, Daniele Donà, Irja Lutsar, Evelyne Jacqz-Aigrain, Paul T Heath, Emmanuel Roilides, Louise Rawcliffe, Basma Bafadal, Ana Alarcon Allen, Clara Alonso-Diaz, Fani Anatolitou, Eugenio Baraldi, Antonio Del Vecchio, Andrea Dotta, Mario Giuffrè, Mari-Liis Ilmoja, Korina Karachristou, Ajit Mahaveer, Paolo Manzoni, Stefano Martinelli, Tuuli Metsvaht, George Mitsiakos, Paul Moriarty, Angeliki Nika, Vana Papaevangelou, Charles Roehr, Laura Sanchez Alcobendas, Kosmas Sarafidis, Tania Siahanidou, Chryssoula Tzialla, Luca Bonadies, Nicola Booth, Paola Catalina Morales-Betancourt, Malaika Cordeiro, Concha de Alba Romero, Javier de la Cruz, Maia De Luca, Daniele Farina, Caterina Franco, Dimitra Gialamprinou, Maarja Hallik, Laura Ilardi, Vincenzo Insinga, Elias Iosifidis, Riste Kalamees, Angeliki Kontou, Zoltan Molnar, Eirini Nikaina, Chryssoula Petropoulou, Mar Reyné, Kassandra Tataropoulou, Pinelopi Triantafyllidou, Adamantios Vontzalidis, A Sarah Walker, Mike Sharland
Journal: The Lancet Child & Adolescent Health (2021)
LBA61 Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study
Authors: L. Paz-Ares, Y. Chen, N. Reinmuth, K. Hotta, D. Trukhin, G. Statsenko, M.J. Hochmair, M. Ozguroglu, J.H. Ji, O. Voitko, A. Poltoratskiy, F. Verderame, L. Havel, I. Bondarenko, G. Losonczy, N.V. Conev, H.L. Broadhurst, T. Dalvi, H. Jiang, J.W. Goldman
Journal: Annals of Oncology (2021)
Hemophagocytic lymphohistiocytosis, what about hair?
Authors: Baptiste Le Calvez, Caroline Thomas, Alice Huault, Elisabeth Cassagnau, Marie C. Béné, Marion Eveillard
Journal: American Journal of Hematology (2021)

A 1-month-old boy, born to nonconsanguineous parents, without notable family health history, presented with febrile pancytopenia and splenomegaly. Clinical examination disclosed no other anomaly, notably no neurological alteration. His initial complete blood count showed normocytic anemia (hemoglobin 105 g/L), thrombocytopenia (84 × 109/L), and neutropenia (0.8 × 109/L) without lymphopenia. Upon worsening of this pancytopenia, associated with persistent fever despite antibiotics, a bone marrow aspirate revealed no blasts but the presence of histiocytes with hemophagocytosis (Image 1A). High serum triglycerides, ferritin, and lactic dehydrogenase were observed at respectively 3.3 mmol/L, 71 000 μg/L, and 788 U/L together with hypofibrinogenemia (1.1 g/L). Molecular tests for toxoplasmosis, HSV, EBV, CMV, HHV6, and parvovirus B19 were negative. Clinical examination revealed the presence of partial albinism with silver-gray hair. This feature associated to the biological anomalies, evoked a diagnosis of Griscelli or Chediak Higashi syndrome. However, bone marrow cells did not contain giant cytoplasmic granulations. Moreover, microscopic analysis of hair revealed clumps of melanin of various sizes irregularly distributed throughout the hair shaft, suggestive of Griscelli syndrome (Image 1B,C). Cerebrospinal fluid (CSF) analysis revealed hyperproteinorachia (0.73 g/L) and 20/μL leucocytes (92% lymphocytes CD4+, CD3+, DR+, CD25−) in favor of asymptomatic central nervous system hemophagocytic lymphohistiocytosis (HLH). Sequencing of the RAB27 gene in a blood sample finally revealed a homozygous missense mutation in exon 3, confirming the diagnosis of type 2 Griscelli syndrome.1 Corticosteroid therapy was initiated followed by alemtuzumab administration. The patient then underwent a haplo-identical allogeneic hematopoietic stem cell transplantation and is well 8 months later. Children with GS2 indeed present with partial albinism, associated with hemophagocytic lymphohistiocytosis. RAB27A deficiency is responsible for a defective exocytosis of cytotoxic granules from T cells and natural killer cells, which may cause secondary immune overactivation leading to HLH. In the absence of treatment, the evolution is rapidly fatal. Although poorly codified, treatment consists in suppression of the triggering factor, control of HLH with chemotherapy or immunotherapy followed by an allo-HSCT.2 The pejorative evolution of this pathology makes its early recognition essential. Thus, children presenting with HLH must systematically benefit from a search for partial albinism. The presence of silver-gray hair makes necessary microscopic examination. The authors declare that they have no conflict of interest. ME and EC performed analyses. BLC, AH and CT treated the patient. BLC, MCB and ME wrote the manuscript.
1403P Toripalimab combined with nab-paclitaxel/docetaxel as second-line treatment in patients with advanced gastric cancer: Preliminary results from a single-arm, open-label phase II trial
Authors: T. Zhang, D. Yu, J. Wang, J. Liu, H. Ma, Z. Lin, M. Jin, J. Zhang, L. Zhao, H. Liu, J. Hu, Q. Zhang
Journal: Annals of Oncology (2021)
13P SY-5609, a highly potent and selective oral CDK7 inhibitor, exhibits robust antitumor activity in preclinical models of KRAS mutant cancers as a single agent and in combination with chemotherapy
Authors: S.H. Henry, L. Johannessen, P. Sawant, A. Lefkovith, N. Ke, W. Dworakowski, G. Hodgson
Journal: Annals of Oncology (2021)
Implementing the 27 PRISMA 2020 Statement items for systematic reviews in the sport and exercise medicine, musculoskeletal rehabilitation and sports science fields: the PERSiST (implementing Prisma in Exercise, Rehabilitation, Sport medicine and SporTs science) guidance
Authors: Clare L Ardern, Fionn Büttner, Renato Andrade, Adam Weir, Maureen C Ashe, Sinead Holden, Franco M Impellizzeri, Eamonn Delahunt, H Paul Dijkstra, Stephanie Mathieson, Michael Skovdal Rathleff, Guus Reurink, Catherine Sherrington, Emmanuel Stamatakis, Bill Vicenzino, Jackie L Whittaker, Alexis A Wright, Mike Clarke, David Moher, Matthew J Page, Karim M Khan, Marinus Winters
Journal: British Journal of Sports Medicine (2021)

Poor reporting of medical and healthcare systematic reviews is a problem from which the sports and exercise medicine, musculoskeletal rehabilitation, and sports science fields are not immune. Transparent, accurate and comprehensive systematic review reporting helps researchers replicate methods, readers understand what was done and why, and clinicians and policy-makers implement results in practice. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement and its accompanying Explanation and Elaboration document provide general reporting examples for systematic reviews of healthcare interventions. However, implementation guidance for sport and exercise medicine, musculoskeletal rehabilitation, and sports science does not exist. The Prisma in Exercise, Rehabilitation, Sport medicine and SporTs science (PERSiST) guidance attempts to address this problem. Nineteen content experts collaborated with three methods experts to identify examples of exemplary reporting in systematic reviews in sport and exercise medicine (including physical activity), musculoskeletal rehabilitation (including physiotherapy), and sports science, for each of the PRISMA 2020 Statement items. PERSiST aims to help: (1) systematic reviewers improve the transparency and reporting of systematic reviews and (2) journal editors and peer reviewers make informed decisions about systematic review reporting quality.
Opioid prescribing among new users for non-cancer pain in the USA, Canada, UK, and Taiwan: A population-based cohort study
Authors: Meghna Jani, Nadyne Girard, David W. Bates, David L. Buckeridge, Therese Sheppard, Jack Li, Usman Iqbal, Shelly Vik, Colin Weaver, Judy Seidel, William G. Dixon, Robyn Tamblyn
Journal: PLoS Medicine (2021)

Background The opioid epidemic in North America has been driven by an increase in the use and potency of prescription opioids, with ensuing excessive opioid-related deaths. Internationally, there are lower rates of opioid-related mortality, possibly because of differences in prescribing and health system policies. Our aim was to compare opioid prescribing rates in patients without cancer, across 5 centers in 4 countries. In addition, we evaluated differences in the type, strength, and starting dose of medication and whether these characteristics changed over time. Methods and findings We conducted a retrospective multicenter cohort study of adults who are new users of opioids without prior cancer. Electronic health records and administrative health records from Boston (United States), Quebec and Alberta (Canada), United Kingdom, and Taiwan were used to identify patients between 2006 and 2015. Standard dosages in morphine milligram equivalents (MMEs) were calculated according to The Centers for Disease Control and Prevention. Age- and sex-standardized opioid prescribing rates were calculated for each jurisdiction. Of the 2,542,890 patients included, 44,690 were from Boston (US), 1,420,136 Alberta, 26,871 Quebec (Canada), 1,012,939 UK, and 38,254 Taiwan. The highest standardized opioid prescribing rates in 2014 were observed in Alberta at 66/1,000 persons compared to 52, 51, and 18/1,000 in the UK, US, and Quebec, respectively. The median MME/day (IQR) at initiation was highest in Boston at 38 (20 to 45); followed by Quebec, 27 (18 to 43); Alberta, 23 (9 to 38); UK, 12 (7 to 20); and Taiwan, 8 (4 to 11). Oxycodone was the first prescribed opioid in 65% of patients in the US cohort compared to 14% in Quebec, 4% in Alberta, 0.1% in the UK, and none in Taiwan. One of the limitations was that data were not available from all centers for the entirety of the 10-year period. Conclusions In this study, we observed substantial differences in opioid prescribing practices for non-cancer pain between jurisdictions. The preference to start patients on higher MME/day and more potent opioids in North America may be a contributing cause to the opioid epidemic.
Effects of an outpatient intervention comprising nurse‐led non‐invasive assessments, telemedicine support and remote cardiologists' decisions in patients with heart failure (<scp>AMULET</scp> study): a randomised controlled trial
Authors: Paweł Krzesiński, Ewa A. Jankowska, Janusz Siebert, Agata Galas, Katarzyna Piotrowicz, Adam Stańczyk, Paweł Siwołowski, Piotr Gutknecht, Paweł Chrom, Piotr Murawski, Andrzej Walczak, Dominika Szalewska, Waldemar Banasiak, Piotr Ponikowski, Grzegorz Gielerak
Journal: European Journal of Heart Failure (2021)

Abstract Aim Prevention of heart failure (HF) hospitalisations and deaths constitutes a major therapeutic aim in patients with HF. The role of telemedicine in this context remains equivocal. We investigated whether an outpatient telecare based on nurse‐led non‐invasive assessments supporting remote therapeutic decisions (AMULET telecare) could improve clinical outcomes in patients after an episode of acute HF during 12‐month follow‐up. Methods and results In this prospective randomised controlled trial, patients with HF and left ventricular ejection fraction (LVEF) ≤49%, after an episode of acute HF within the last 6 months, were randomly assigned to receive either an outpatient telecare based on nurse‐led non‐invasive assessments ( n = 300) (AMULET model) or standard care ( n = 305). The primary composite outcome of unplanned HF hospitalisation or cardiovascular death occurred in 51 (17.1%) patients in the telecare group and 73 (23.9%) patients in the standard care group up to 12 months after randomization [hazard ratio (HR) 0.69, 95% confidence interval (CI) 0.48–0.99; P = 0.044]. The implementation of AMULET telecare, as compared to standard care, reduced the risk of first unplanned HF hospitalisation (HR 0.62, 95% CI 0.42–0.91; P = 0.015) as well as the risk of total unplanned HF hospitalisations (HR 0.64, 95% CI 0.41–0.99; P = 0.044).There was no difference in cardiovascular mortality between the study groups (HR 1.03, 95% CI 0.54–1.67; P = 0.930). Conclusions AMULET telecare as compared to standard care significantly reduced the risk of HF hospitalisation or cardiovascular death during 12‐month follow‐up among patients with HF and LVEF ≤49% after an episode of acute HF.
Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score Cutoffs for Disease Activity States in Juvenile Idiopathic Arthritis
Authors: Chiara Trincianti, Evert Hendrik Pieter Van Dijkhuizen, Alessandra Alongi, Marta Mazzoni, Joost F. Swart, Irina Nikishina, Pekka Lahdenne, Lidia Rutkowska‐Sak, Tadej Avcin, Pierre Quartier, Violeta Panaviene, Yosef Uziel, Chris Pruunsild, Veronika Vargova, Soamarat Vilaiyuk, Pavla Dolezalova, Sarah Ringold, Marco Garrone, Nicolino Ruperto, Angelo Ravelli, Alessandro Consolaro
Journal: Arthritis & Rheumatology (2021)

Objective To develop and validate new Juvenile Arthritis Disease Activity Score 10 (JADAS10) and clinical JADAS10 (cJADAS10) cutoffs to separate the states of inactive disease (ID), minimal disease activity (MiDA), moderate disease activity (MoDA), and high disease activity (HDA) in children with oligoarthritis and with rheumatoid factor–negative polyarthritis, based on subjective disease assessment by the treating pediatric rheumatologist. Methods The cutoffs definition cohort was composed of 1,936 patients included in the multinational Epidemiology, Treatment and Outcome of Childhood Arthritis (EPOCA) study. Using the subjective physician rating as an external criterion, 4 methods were applied to identify the cutoffs: mapping, Youden index, 90% specificity, and maximum agreement. The validation cohort included 4,014 EPOCA patients, patients from 2 randomized trials, and 88 patients from the PharmaChild registry. Cutoff validation was conducted by assessing discriminative and predictive ability. Results The JADAS10 cutoffs were 1.4, 4, and 13, respectively, for oligoarthritis and 2.7, 6, and 17, respectively, for polyarthritis. The cJADAS10 cutoffs were 1.1, 4, and 12, respectively, for oligoarthritis and 2.5, 5, and 16, respectively, for polyarthritis. The cutoffs discriminated strongly among different levels of pain and morning stiffness, between patients who were and those who were not prescribed a new medication, and between different levels of improvement in clinical trials. Achievement of ID and MiDA according to the new JADAS cutoffs at least twice in the first year of disease predicted better outcome at 2 years. Conclusion The 2021 JADAS and cJADAS cutoffs revealed good metrologic properties in both definition and validation samples, and are therefore suitable for use in clinical trials and routine practice.
LBA57 Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)
Authors: T. Conroy, P. Hammel, A. Turpin, C. Belletier, A. Wei, E. Mitry, A. Lopez, E. Francois, P. Artru, J. Biagi, T. Lecomte, E. Assenat, R. Faroux, M. Ychou, O. Bouche, A. Lambert, L. Monard, P. Rat, F. Castan, J-B. Bachet
Journal: Annals of Oncology (2021)
Trends in Cardiovascular Risk Factors in US Adults by Race and Ethnicity and Socioeconomic Status, 1999-2018
Authors: Jiang He, Zhengbao Zhu, Joshua D. Bundy, Kirsten S. Dorans, Jing Chen, L. Lee Hamm
Journal: JAMA (2021)

After decades of decline, the US cardiovascular disease mortality rate flattened after 2010, and racial and ethnic differences in cardiovascular disease mortality persisted.
1289P Intracranial response (ICR) following immunotherapy in non-small cell lung cancer (NSCLC) patients with untreated brain metastasis (BM)
Authors: B. Bjoernhart, K.H. Hansen, J.T. Asmussen, T.L. Jørgensen, J. Herrstedt, T. Schytte
Journal: Annals of Oncology (2021)
816TiP Randomized phase III trial on niraparib - TSR-042 (dostarlimab) vs physician’s choice CHEmotherapy in recurrent ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
Authors: D. Lorusso, L. Musacchio, S. Pignata, E.I. Braicu, D. Cibula, N. Colombo, J-S. Frenel, F. Zagouri, V. Carbone, V. Ghizzoni, S. Giolitto, E. Giudice, C. Landolfo, M.T. Perri, C. Ricci, V. Salutari, G. Scambia
Journal: Annals of Oncology (2021)
Nasal Sinus Surgery, with Operations on Nose and Throat.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal